Idera to Present at Two June Investor Healthcare Conferences

CAMBRIDGE, Mass. and EXTON, Pa., June 07, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 4:00 p.m. Eastern Time at the Grand Hyatt in New York City.

The company is also announcing that Vincent Milano, Idera’s Chief Executive Officer will present at the 2016 JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 2:00 p.m. Eastern Time at the St. Regis Hotel in New York City.

Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at Archived versions will also be available on the Company’s website after the event for 90 days.

About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit

Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile)

Source:Idera Pharmaceuticals, Inc.